Two more null responders relapse in Gilead small hep C trial; G1 naive data due in April
This article was originally published in Scrip
Executive Summary
Two more patients in a small study of genotype 1 null responder patients relapsed with four weeks of completing 12 weeks of Gilead Sciences' experimental hepatitis C drug GS-7977, a nucleoside analogue, plus ribavirin, researchers said at the recent Conference on Retroviruses and Opportunistic Infections.